system
A chat on subreddit /r/wallstreetbets
human
The analyst was vouching for ACST, which is a tiny company, with a krill oil based product in development. There is no way they can avoid a multi-year CVOT trial if they want to compete with Vascepa. If ACST's P3 trial is successful, they'll get a label covering &gt;500mg TG level patients. Vascepa's upcoming label will be 20-times bigger.

gpt
I just read up on that. Yeah, I have no idea what this guy was thinking.